By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Oxymetazoline (monograph)
Drugs

Oxymetazoline (monograph)

https://themeditary.com/drug/oxymetazoline-monograph-5254.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 11, 2023  Additional Content by TheMediTary.Com

Generic name: ... show all 14 brands

Availability: Rx and/or otc

Pregnancy & Lactation: Risk data not available

Brand names: Upneeq, Visine long lasting, Oxymetazoline ophthalmic

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Oxymetazoline (monograph)?

Introduction

Vasoconstrictor; an imidazoline-derivative sympathomimetic amine.

Uses for Oxymetazoline

Nasal Congestion

Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other upper respiratory allergies.

As effective as other topical vasoconstrictors.

Labeled and has been used for self-medication for temporary relief of nasal congestion associated with sinusitis; however, efficacy data are lacking and/or controversial. In October 2005, FDA issued final rule to remove this indication from labeling of OTC nasal decongestants. Compliance date for preparations with annual sales <$25,000 is October 11, 2007; compliance date for all other preparations is April 11, 2007.

Conjunctival Congestion

Self-medication for temporary relief of ocular redness due to minor irritation.

Otitic Barotrauma

Has been used for self-medication for symptomatic prevention of otitic barotrauma† [off-label] (aerotitis [barotitis] media); however, no more effective than placebo.

Related/similar drugs

phenylephrine ophthalmic, brimonidine ophthalmic, fluorometholone ophthalmic, Upneeq, FML, naphazoline ophthalmic

Oxymetazoline Dosage and Administration

Administration

Administer topically to nasal mucosa or conjunctiva.

Intranasal Administration

Administer nasal solution intranasally as sprays or nasal pumps.

Prior to initial use of metered sprays, prime nasal inhaler by depressing the pump firmly several times.

Administer nasal spray or pump into each nostril while head is erect.

Ophthalmic Administration

Administer ophthalmic solution topically to the conjunctiva.

Avoid contamination of the dropper tip.

Remove contact lenses before administering ophthalmic solution.

Do not administer discolored or cloudy solutions.

Dosage

Available as oxymetazoline hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Nasal Congestion
Intranasal

For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.

Conjunctival Congestion
Ophthalmic

For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Adults

Nasal Congestion
Intranasal

For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.

Conjunctival Congestion
Ophthalmic

For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Prescribing Limits

Pediatric Patients

Nasal Congestion
Intranasal

Self-medication in children ≥6 years of age: Maximum of 2 times (2 doses) in a 24-hour period. (See Advice to Patients.)

Adults

Nasal Congestion
Intranasal

Self-medication: Maximum of 2 times (2 doses) in a 24-hour period. (See Advice to Patients.)

Warnings

Contraindications

  • Known hypersensitivity to oxymetazoline or any ingredient in the formulation.

  • Known sensitivity to the pharmacologic effects of adrenergic drugs.

Warnings/Precautions

General Precautions

Overuse

Possible irritation of nasal mucosa and adverse systemic effects (particularly in children) with excessive dosage and/or prolonged or too frequent intranasal use. Possible rebound nasal congestion or ocular hyperemia (redness); avoid prolonged use. (See Advice to Patients.)

Accidental ingestion of imidazoline derivatives (i.e., oxymetazoline, naphazoline, tetrahydrozoline) in children has resulted in serious adverse events requiring hospitalization (e.g., coma, bradycardia, decreased respiration, sedation, somnolence). (See Pediatric Use under Cautions and also see Advice to Patients.)

Sympathomimetic Effects

With intranasal use, possible headache, hypertension, cardiac irregularities (e.g., palpitation, reflex bradycardia), nervousness, nausea, dizziness, and insomnia. Use with caution and under direction of a clinician in patients with thyroid disease (e.g., hyperthyroidism), heart disease (including angina), hypertension, advanced arteriosclerotic conditions, or diabetes mellitus; in patients experiencing difficulty in urination secondary to prostatic enlargement; or in patients receiving monoamine oxidase (MAO) inhibitors.

Glaucoma

Patients with narrow-angle glaucoma should consult a clinician before using ophthalmic solution.

Specific Populations

Pregnancy

Category C.

Lactation

Not known whether oxymetazoline is distributed into milk. Use with caution in nursing women.

Pediatric Use

0.05% nasal solution or 0.025% ophthalmic solution not recommended for self-medication in children <6 years of age.

Possible irritation of nasal mucosa and adverse systemic effects (including profound CNS depression) associated with excessive dosage, prolonged or too frequent use, or inadvertent ingestion of nasal solution.

Accidental ingestion of OTC ophthalmic solutions or nasal sprays containing imidazoline derivatives (i.e., oxymetazoline, naphazoline, tetrahydrozoline) in children has resulted in serious adverse events requiring hospitalization, including nausea, vomiting, lethargy, tachycardia, decreased respiration, bradycardia, hypotension, hypertension, sedation, somnolence, mydriasis, stupor, hypothermia, drooling, and coma. Keep out of reach of children. (See Advice to Patients.)

Common Adverse Effects

Nasal solution: transient burning, stinging, sneezing, increased nasal discharge or dryness of nasal mucosa.

How should I use Oxymetazoline (monograph)

Administration

Administer topically to nasal mucosa or conjunctiva.

Intranasal Administration

Administer nasal solution intranasally as sprays or nasal pumps.

Prior to initial use of metered sprays, prime nasal inhaler by depressing the pump firmly several times.

Administer nasal spray or pump into each nostril while head is erect.

Ophthalmic Administration

Administer ophthalmic solution topically to the conjunctiva.

Avoid contamination of the dropper tip.

Remove contact lenses before administering ophthalmic solution.

Do not administer discolored or cloudy solutions.

Dosage

Available as oxymetazoline hydrochloride; dosage expressed in terms of the salt.

Pediatric Patients

Nasal Congestion
Intranasal

For self-medication in children ≥6 years of age: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.

Conjunctival Congestion
Ophthalmic

For self-medication in children ≥6 years of age: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Adults

Nasal Congestion
Intranasal

For self-medication: 2 or 3 sprays of a 0.05% nasal solution in each nostril every 10–12 hours (usually in the morning and evening), up to 2 times daily.

Conjunctival Congestion
Ophthalmic

For self-medication: 1 or 2 drops of a 0.025% ophthalmic solution in the affected eye(s) every 6 hours as needed.

Prescribing Limits

Pediatric Patients

Nasal Congestion
Intranasal

Self-medication in children ≥6 years of age: Maximum of 2 times (2 doses) in a 24-hour period. (See Advice to Patients.)

Adults

Nasal Congestion
Intranasal

Self-medication: Maximum of 2 times (2 doses) in a 24-hour period. (See Advice to Patients.)

More about Oxymetazoline (monograph) (... show all 14 brands)

Oxymetazoline (monograph) Side Effects
Drug images
Side effects
Drug class: Drugs

Related treatment guides

Eye Redness
Blepharoptosis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by